SHORT-TERM USE OF RIVAROXABAN
Short-term use of rivaroxaban can reduce incidences of radial artery occlusion (RAO) by 50%, according to a study presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2022 conference in Boston.
The RIVARAD trial found a 10-mg dose of rivaroxaban given to patients for 7 days after undergoing a transradial coronary procedure did reduce RAO incidences at 30 days vs. control group (6.9% versus 13%; p=0.011, odds ratio `{`OR`}`, 0.5; 95% confidence interval `{`CI`}`, 0.27–0.91).
Will Chu, CRTonline.org
Posted: 09/19/2022
PREVENTION OF RADIAL ARTERY OCCLUSION WITH RIVAROXABAN
Aaysha Cader interviews Rania Hammami, Principal Investigator of the RIVARAD trial. They discuss the design and results of the trial which was presented during #TCT2022.
RIVARAD is the first multicentric randomized trial with 30-day RAOs as the primary endpoint, which proved the efficacy of short-term use of rivaroxaban in preventing RAO in real-world daily practice using the radial approach.
PCRonline: Aaysha Cader / Rania Hammami
Aaysha Cader @aayshacader Interventional cardiologist / Cardiologist Ibrahim Cardiac Hospital and Research Institute - Dhaka, Bangladesh Rania Hammami @RHammami_cardio Interventional cardiologist / Cardiologist Hedi Chaker Hospital - Sfax, Tunisia
PREVENTION OF RADIAL ARTERY OCCLUSION WITH RIVAROXABAN
The RIVARAD trial showed that 7 days of rivaroxaban may prevent radial artery occlusion.
Description:
The goal of the trial was to evaluate rivaroxaban compared with control among individuals who underwent cardiac catheterization by transradial access.
Study Design
Randomized
Parallel
Open-label
Anthony A. Bavry, MD, MPH, FACC
Summary Reviewer: Deepak L. Bhatt, MD, MPH, FACC Trial Sponsor: Philadelphia Pharma (Tunisia) Date Presented: 09/19/2022 Date Published: 09/19/2022
